Follow-The-Filings

Security · featured owners

VRTX Vertex Pharmaceuticals Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 4 Owners
  • Max 1.5%
  • $30M
  • 3 reduce

VRTX (Vertex Pharmaceuticals Inc.) is held in 4 featured 13F books as of 2026 Q2. Tweedy, Browne Co. is the largest tracked holder by portfolio weight (1.5%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 1.5% (Tweedy, Browne Co.) · not free-float ownership

  1. Tweedy, Browne Co. reduce 1.5%
  2. Torray Investment Partners reduce 1.0%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Tweedy, Browne Co. 2026 Q2 1.5% Reduce −0.7% 40,121 $20M history
Torray Investment Partners 2026 Q2 1.0% Reduce −1.1% 15,215 $8M history
Ron Baron - Bamco Inc. (Baron Capital) 2026 Q2 <0.01% Reduce −20.0% 6,000 $3M history
Kentucky Trust Co. - Kentucky Trust 2026 Q2 <0.01% Hold 5 $2K history

4 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 9 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 5.02 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 1.01,7.01,8.01,9.01 Filing Doc
8-K 5.02,5.07 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02 Filing Doc
DEFA14A Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 16 rows shown

Filed Form Detail Links
4 Period Sep 8, 2026 Filing Doc
4 Period Aug 28, 2026 Filing Doc
4 Period Aug 27, 2026 Filing Doc
4 Period Jul 21, 2026 · 2 forms Filing Doc
4 Period Jul 15, 2026 · 2 forms Filing Doc
4 Period Jul 2, 2026 · 2 forms Filing Doc
4 Period Jul 1, 2026 Filing Doc
4 Period Jun 26, 2026 Filing Doc
4 Period Jun 18, 2026 Filing Doc
4 Period Jun 15, 2026 Filing Doc
4 Period Jun 5, 2026 Filing Doc
4 Period Jun 1, 2026 Filing Doc
4 Period May 29, 2026 Filing Doc
4 Period May 15, 2026 · 2 forms Filing Doc
4 Period May 12, 2026 Filing Doc
4 Period May 1, 2026 · 6 forms Filing Doc

Updated 4 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $9.87B $11.02B $12B
Gross profit * $8.61B $9.49B $10.35B
Gross margin * 87.2% 86.1% 86.2%
Net income $3.62B -$0.536B $3.95B
Net margin * 36.7% -4.9% 32.9%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $14.14B $9.6B $11.2B
Total non-current assets * $8.59B $12.94B $14.44B
Total assets $22.73B $22.53B $25.64B
Total current liabilities $3.55B $3.56B $3.86B
Total non-current liabilities * $1.6B $2.56B $3.12B
Total equity $17.58B $16.41B $18.67B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $3.54B -$0.493B $3.63B
Cash from investing -$3.14B -$3.77B -$0.945B
Cash from financing -$0.562B -$1.49B -$2.26B
Net change in cash -$0.14B -$5.8B $0.516B

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders